Details for Patent: 8,058,280
✉ Email this page to a colleague
Which drugs does patent 8,058,280 protect, and when does it expire?
Patent 8,058,280 protects MYFEMBREE and ORGOVYX and is included in two NDAs.
This patent has thirty-four patent family members in twenty-five countries.
Summary for Patent: 8,058,280
| Title: | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
| Abstract: | The present invention provides a compound represented by the formula: ##STR00001## wherein R.sup.1 is a C.sub.1-4 alkyl; R.sup.2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2') a hydroxy group, (3') a C.sub.1-4 alkyl and (4') a C.sub.1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1') a halogen, (2') a C.sub.1-4 alkoxy-C.sub.1-4 alkyl, (3') a mono-C.sub.1-4 alkyl-carbamoyl-C.sub.1-4 alkyl, (4') a C.sub.1-4 alkoxy and (5') a mono-C.sub.1-4 alkylcarbamoyl-C.sub.1-4 alkoxy, or the like; R.sup.3 is a C.sub.1-4 alkyl; R.sup.4 is a C.sub.1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity. |
| Inventor(s): | Cho; Nobuo (Osaka, JP), Imada; Takashi (Osaka, JP), Hitaka; Takenori (Osaka, JP), Miwa; Kazuhiro (Osaka, JP), Kusaka; Masami (Osaka, JP), Suzuki; Nobuhiro (Tsukuba, JP) |
| Assignee: | Takeda Pharmaceutical Company Limited (Fujisawa-Shi, JP) |
| Application Number: | 11/848,939 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,058,280
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myovant Sciences | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Sumitomo Pharma | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,058,280
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2003-020854 | Jan 29, 2003 |
International Family Members for US Patent 8,058,280
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004207706 | ⤷ Try a Trial | |||
| Brazil | PI0407082 | ⤷ Try a Trial | |||
| Canada | 2514407 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
